The shares of Qiagen and Merck KGaA were at the bottom of the index on Monday with losses in the barely changed Dax. JPMorgan analyst Richard Vosser sees slight headwinds for European diagnostics specialists in particular due to cuts in research spending in the US healthcare system. Qiagen continued its slide to its lowest level since July 2024 and is now down 13 percent for the year; Merck KGaA is down two percent.
The shares of pharmaceutical and laboratory supplier Sartorius remained under pressure with a drop of just under one percent. The jump in the share price at the end of January following preliminary business figures for the past year is now completely gone. However, after a very weak 2024, the shares are still up around 16 percent in 2025.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.